Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents

Research output: Contribution to journalReviewResearchpeer-review

  1. Targeting BKCa Channels in Migraine: Rationale and Perspectives

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Safety of Second-Generation Antipsychotics During Pregnancy: A Clinically Focused Review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Klinisk Neurologi og Neurokirurgi

    Research output: Book/ReportBookEducation

  3. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Treatment of multiple sclerosis (MS) has improved considerably over the last decade because of new insights into MS pathology and biotechnological advances. This has led to the development of new potent pharmaceutical compounds targeting different processes in the complex autoimmune pathology leading to chronic central nervous system (CNS) demyelination, neural loss, and, finally, neurological disability. Although a number of disease-modifying treatments are available for the treatment of the inflammatory phase of MS, there is still a need for highly efficacious therapies with an acceptable safety profile in order to gain therapeutic control early in the disease course. Monoclonal antibodies have proven to be some of the most efficacious disease-modifying therapies in the field of MS, and recent developments in clinical research hold promise for new compounds fulfilling the need for improved safety and high efficacy. We review recent developments in the field of therapeutic monoclonal antibodies used for the treatment of MS and current information on the mode of action, efficacy, and safety of existing and emerging therapeutic monoclonal antibodies as well as their place within the context of different treatment strategies. Finally, we consider the most important future developments.

Original languageEnglish
JournalCNS Drugs
Volume31
Issue number5
Pages (from-to)357-371
Number of pages15
ISSN1172-7047
DOIs
Publication statusPublished - May 2017

    Research areas

  • Journal Article, Review

ID: 52213987